Rein Therapeutics (RNTX) Net Cash Flow (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Net Cash Flow of $1.2 million for Q1 2026, up 122.62% year-over-year from $552504.1 in Q1 2025, and up 250.92% quarter-over-quarter from -$815000.0 in Q4 2025.
Rein Therapeutics (RNTX) Net Cash Flow (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Net Cash Flow for 11 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 122.62% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at -$2.9 million (up 36.65% YoY), while the FY2025 annual figure was -$9.6 million, down 114.76% from the prior year.
- Net Cash Flow climbed to $1.2 million in Q1 2026 per RNTX's latest filing, from -$815000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $9.9 million in Q2 2024 and bottomed at -$5.4 million in Q1 2025.
- Historically, Net Cash Flow has averaged $54529.4 across 5 years, with a median of -$815000.0 in 2025.
- Annual changes were most pronounced in 2023 — Net Cash Flow jumped 2907.82% — and 2024, when it tumbled 303.59%.
- Rein Therapeutics' Net Cash Flow stood at $355000.0 in 2022, then soared by 1394.93% to $5.3 million in 2023, then sank by 190.65% to -$4.8 million in 2024, then soared by 83.06% to -$815000.0 in 2025, then surged by 250.92% to $1.2 million in 2026.
- Business Quant data shows RNTX's Net Cash Flow at $1.2 million in Q1 2026, -$815000.0 in Q4 2025, and -$1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 39.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.18 Mn |
| Jun 30, 2026 | 39.18 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | -815,000.00 |
| Dec 31, 2025 | -815,000.00 |
| Sep 30, 2025 | -1.65 Mn |
| Sep 30, 2025 | -1.65 Mn |
| Jun 30, 2025 | -1.71 Mn |
| Jun 30, 2025 | -1.71 Mn |
| Mar 31, 2025 | -5.44 Mn |
| Mar 31, 2025 | -5.44 Mn |
| Dec 31, 2024 | -4.81 Mn |
| Dec 31, 2024 | -4.81 Mn |
| Sep 30, 2024 | -4.27 Mn |
| Sep 30, 2024 | -4.27 Mn |
| Jun 30, 2024 | 9.87 Mn |
| Jun 30, 2024 | 9.87 Mn |
| Mar 31, 2024 | -5.27 Mn |
| Mar 31, 2024 | -5.27 Mn |